Showing 2561-2570 of 3329 results for "".
- Phase 2 DaxibotulinumtoxinA Data Highlight Efficacy for Upper Facial Lineshttps://modernaesthetics.com/news/phase-2-daxibotulinumtoxina-data-highlight-efficacy-for-upper-facial-lines/2473032/Topline efficacy and safety results from the phase 2 multicenter, open-label study of Revance's investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, show high levels of patient satisfaction. The 36-week study enrolled 48
- Revance Update: FDA Defers Approval of DaxibotulinumtoxinA Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspectionhttps://modernaesthetics.com/news/revance-update-fda-defers-approval-of-daxibotulinumtoxina-due-to-covid-19-related-travel-restrictions-impacting-manufacturing-site-inspection/2473027/The U.S. Food and Drug Administration (FDA) deferred a decision on the Biologics License Application (BLA) for Revance’s DaxibotulinumtoxinA for Injection, an investigational neuromodulator product for the treatment of moderate to severe glabellar lines. In a communication r
- ISAPS Reports Continuing Rise in Aesthetic Surgery Worldwidehttps://modernaesthetics.com/news/isaps-reports-continuing-rise-in-aesthetic-surgery-worldwide/2473026/Total surgical and nonsurgical cosmetic procedures increased by 7.4 percent in 2019, according to the International Society of Aesthetic Plastic Surgery (ISAPS) 2019 Global Survey. The 7.4 perce
- ZO Skin Health Adds Colleen Goggins to Board of Directorshttps://modernaesthetics.com/news/zo-skin-health-adds-colleen-goggins-to-board-of-directors/2473024/Colleen Goggins is joining ZO Skin Health’s board of directors. This follows the recent acquisition of a majority stake in the business in October by funds managed by Blackstone Tactical Opportunities. As a partner and counsellor to a large variety of bu
- Crown Aesthetics’ SkinPen Precision Scores Class IIa CE Certification from the British Standards Institutionhttps://modernaesthetics.com/news/crown-aesthetics-skinpen-precision-scores-class-iia-ce-certification-from-the-british-standards-institution/2473019/The British Standards Institution (BSI) granted a Class IIa CE Certification mark to Crown Aesthetics’ SkinPen Precision. The certification confirms SkinPen as a treatment to improve the appearance of facial acne scars in adults aged 22 years or older and to improve the appe
- Ransomware Alert: Government Advisory Suggests Threat to Healthcare Systemhttps://modernaesthetics.com/news/ransomware-alert-government-advisory-suggests-threat-to-healthcare-system/2473012/A new advisory coauthored by the Cybersecurity and Infrastructure Security Agency (CISA), the Federal Bureau of Investigation (FBI), and the Department of Health and Human Services (HHS) warns of the potential for ransomware attacks against hospitals and medical systems. “CI
- Aesthetics Biomedical Inaugurates Microneedling Dayhttps://modernaesthetics.com/news/aesthetics-biomedical-inaugurates-microneedling-day/2473008/It’s official! #NationalMicroneedlingDay is October 26. Aesthetics Biomedical® (ABM) says the day has been recognized by the National Day Archives as an official holiday on the National Day Registry™ to honor the leading radiofrequency microneedling treatment in th
- BTL Launches Emsculpt NEOhttps://modernaesthetics.com/news/btl-launches-emsculpt-neo/2473004/The first procedure to combine radio frequency heating and high-intensity focused electromagnetic waves into a single therapy, Emsculpt NEO from BTL, has launched. It is FDA-cleared to eliminate fat cells non-invasively. Emsc
- Allergan Buys Luminera Dermal-Filler Businesshttps://modernaesthetics.com/news/allergan-buys-luminera-dermal-filler-business/2473000/Allergan Aesthetics, an AbbVie company, has acquired Luminera's full dermal filler portfolio and R&D pipeline. Luminera is a privately held aesthetics company based in Israel with a portfolio and pipeline of dermal filler products. "
- Cynosure Taps Vet Dr. Rafael Sierra for R&D Positionhttps://modernaesthetics.com/news/cynosure-taps-vet-rafael-sierra-phd-for-rd-position/2472992/Rafael Sierra, PhD is back at Cynosure. The former Chief Technology Officer is now an R&D Advisor. "Dr. Sierra's passion for the science behind medical aesthetics and inherent knowledge of its clinical application are unparalleled," says Todd